Enlivex Therapeutics

This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies

First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM

FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies

First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment

Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment

Enlivex Therapeutics Recent News

A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera

Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments

Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and difficult to treat disease.

Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That

One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms.

Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022.